Intravitreal therapeutic nanoparticles for age-related macular degeneration: Design principles, progress and opportunities

IF 15.9 1区化学 Q1 CHEMISTRY, PHYSICAL

Advances in Colloid and Interface Science Pub Date : 2024-05-21 DOI:10.1016/j.cis.2024.103200

Yuhang Zhang , Stephanie Watson , Yogambha Ramaswamy , Gurvinder Singh

{"title":"Intravitreal therapeutic nanoparticles for age-related macular degeneration: Design principles, progress and opportunities","authors":"Yuhang Zhang , Stephanie Watson , Yogambha Ramaswamy , Gurvinder Singh","doi":"10.1016/j.cis.2024.103200","DOIUrl":null,"url":null,"abstract":"<div><p>Age-related macular degeneration (AMD) is a leading cause of vision loss in the elderly. The current standard treatment for AMD involves frequent intravitreal administrations of therapeutic agents. While effective, this approach presents challenges, including patient discomfort, inconvenience, and the risk of adverse complications. Nanoparticle-based intravitreal drug delivery platforms offer a promising solution to overcome these limitations. These platforms are engineered to target the retina specifically and control drug release, which enhances drug retention, improves drug concentration and bioavailability at the retinal site, and reduces the frequency of injections. This review aims to uncover the design principles guiding the development of highly effective nanoparticle-based intravitreal drug delivery platforms for AMD treatment. By gaining a deeper understanding of the physiology of ocular barriers and the physicochemical properties of nanoparticles, we establish a basis for designing intravitreal nanoparticles to optimize drug delivery and drug retention in the retina. Furthermore, we review recent nanoparticle-based intravitreal therapeutic strategies to highlight their potential in improving AMD treatment efficiency. Lastly, we address the challenges and opportunities in this field, providing insights into the future of nanoparticle-based drug delivery to improve therapeutic outcomes for AMD patients.</p></div>","PeriodicalId":239,"journal":{"name":"Advances in Colloid and Interface Science","volume":"329 ","pages":"Article 103200"},"PeriodicalIF":15.9000,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0001868624001234/pdfft?md5=2ec5caba0bcf0bd9c46260a47b6c0617&pid=1-s2.0-S0001868624001234-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Colloid and Interface Science","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001868624001234","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Age-related macular degeneration (AMD) is a leading cause of vision loss in the elderly. The current standard treatment for AMD involves frequent intravitreal administrations of therapeutic agents. While effective, this approach presents challenges, including patient discomfort, inconvenience, and the risk of adverse complications. Nanoparticle-based intravitreal drug delivery platforms offer a promising solution to overcome these limitations. These platforms are engineered to target the retina specifically and control drug release, which enhances drug retention, improves drug concentration and bioavailability at the retinal site, and reduces the frequency of injections. This review aims to uncover the design principles guiding the development of highly effective nanoparticle-based intravitreal drug delivery platforms for AMD treatment. By gaining a deeper understanding of the physiology of ocular barriers and the physicochemical properties of nanoparticles, we establish a basis for designing intravitreal nanoparticles to optimize drug delivery and drug retention in the retina. Furthermore, we review recent nanoparticle-based intravitreal therapeutic strategies to highlight their potential in improving AMD treatment efficiency. Lastly, we address the challenges and opportunities in this field, providing insights into the future of nanoparticle-based drug delivery to improve therapeutic outcomes for AMD patients.

Abstract Image

查看原文本刊更多论文

用于老年性黄斑变性的玻璃体内治疗纳米粒子：设计原则、进展与机遇

老年性黄斑变性（AMD）是导致老年人视力丧失的主要原因。目前治疗老年黄斑变性的标准方法是经常在玻璃体内注射治疗药物。这种方法虽然有效，但也带来了挑战，包括患者不适、不便和不良并发症的风险。基于纳米粒子的玻璃体内给药平台为克服这些局限性提供了一种很有前景的解决方案。这些平台可特异性地靶向视网膜并控制药物释放，从而提高药物保留率，改善视网膜部位的药物浓度和生物利用度，并减少注射次数。本综述旨在揭示基于纳米粒子的高效视网膜内给药平台的设计原理，从而开发出治疗老年性黄斑变性的药物。通过深入了解眼屏障的生理学和纳米粒子的理化特性，我们为设计玻璃体内纳米粒子奠定了基础，以优化药物输送和药物在视网膜中的保留。此外，我们还回顾了最近基于纳米粒子的玻璃体内治疗策略，以强调它们在提高 AMD 治疗效率方面的潜力。最后，我们探讨了这一领域的挑战和机遇，为基于纳米粒子的药物递送改善 AMD 患者治疗效果的未来提供了真知灼见。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Colloid and Interface Science 化学-物理化学

CiteScore

28.50

自引率

2.60%

发文量

175

审稿时长

31 days

期刊介绍： "Advances in Colloid and Interface Science" is an international journal that focuses on experimental and theoretical developments in interfacial and colloidal phenomena. The journal covers a wide range of disciplines including biology, chemistry, physics, and technology. The journal accepts review articles on any topic within the scope of colloid and interface science. These articles should provide an in-depth analysis of the subject matter, offering a critical review of the current state of the field. The author's informed opinion on the topic should also be included. The manuscript should compare and contrast ideas found in the reviewed literature and address the limitations of these ideas. Typically, the articles published in this journal are written by recognized experts in the field.